Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer.

Trial Profile

Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 May 2008 Results to be presented at the Annual Meeting of the American Society of Clinical Oncology 2008, according to a Bayer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top